Giant-Cell Arteritis Market Report 2026

Giant-Cell Arteritis Market Overview

• Giant-Cell Arteritis market size has reached to $1.12 billion in 2025 • Expected to grow to $1.39 billion in 2030 at a compound annual growth rate (CAGR) of 4.3% • Growth Driver: Embracing Personalized Medicine A Shift Towards Tailored Healthcare Solutions • Market Trend: Major Developments In Giant-Cell Arteritis Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Giant-Cell Arteritis Market?

Giant-cell arteritis (GCA) is a type of vasculitis, or inflammation of blood vessels, predominantly affecting medium to large arteries. It commonly involves the temporal arteries, leading to headaches, scalp tenderness, and vision problems. GCA is characterized by inflammation of the vessel walls, potentially leading to serious complications such as blindness or stroke if untreated. Treatment typically involves high-dose corticosteroids to suppress inflammation and prevent complications. The main giant-cell arteritis therapeutics are prednisone, methotrexate, tocilizumab, and aspirin. Prednisone is a corticosteroid medication that suppresses inflammation and the immune system. It has various mechanisms of action, such as corticosteroids, immunosuppressive agents, anticoagulants, and others, and it is administered through oral, intravenous, subcutaneous, and other routes.

What Is The Giant-Cell Arteritis Market Growth Forecast?

The giant-cell arteritis market size is expected to see steady growth in the next few years. It will grow to $1.39 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to biologic drug approvals, growth in immunology research, improved diagnostic protocols, personalized vasculitis treatment, expansion of specialty clinics. Major trends in the forecast period include increased adoption of biologic therapies, rising focus on early and accurate diagnosis, expanded use of corticosteroid-sparing treatments, improved long-term disease monitoring, growing awareness of vision loss prevention.

Global Giant-Cell Arteritis Market Segmentation

1) By Therapeutics: Prednisone, Methotrexate, Tocilizumab, Aspirin 2) By Mechanism Of Action: Corticosteroids, Immunosuppressive Agents, Anticoagulants, Other Mechanisms Of Action 3) By Route Of Administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration Subsegments: 1) By Prednisone: Oral Prednisone, Intravenous (IV) Prednisone, Low-Dose Prednisone Therapy, High-Dose Prednisone Therapy 2) By Methotrexate: Oral Methotrexate, Subcutaneous Methotrexate, Methotrexate Monotherapy, Methotrexate Combination Therapy 3) By Tocilizumab: Intravenous Tocilizumab, Subcutaneous Tocilizumab, Tocilizumab Monotherapy, Tocilizumab In Combination With Corticosteroids 4) By Aspirin: Low-Dose Aspirin Therapy, Aspirin For Cardiovascular Risk Management, Aspirin In Combination Therapy, Enteric-Coated Aspirin

What Is The Driver Of The Giant-Cell Arteritis Market?

Growing emphasis on personalized medicine is expected to propel the growth of the giant-cell arteritis market going forward. Personalized medicine involves tailoring medical treatment to individual characteristics, such as genetics, lifestyle, and environment. Personalized medicine is increasing due to advancements in genomics, biotechnology, and data analytics, enabling targeted therapies that improve treatment efficacy and reduce adverse effects for individuals. Personalized medicine can aid in giant-cell arteritis (GCA) by allowing for targeted therapies based on individual patient factors such as genetic predispositions, immune profiles, and disease manifestations. For instance, in February 2024, the Personalized Medicine Coalition (PMC), a U.S.-based non-profit organization, reported that personalized medicines accounted for over one-third of new drug approvals by the U.S. Food and Drug Administration (FDA) for the fourth consecutive year in 2023. During that year, the FDA approved 16 new personalized treatments tailored for rare diseases, a significant increase from six approvals in 2022. Additionally, the approvals in 2023 encompassed seven cancer medications and three treatments for various other diseases and conditions. Therefore, growing emphasis on personalized medicine is driving the growth of the giant-cell arteritis industry.

Key Players In The Global Giant-Cell Arteritis Market

Major companies operating in the giant-cell arteritis market are Roche, AbbVie, Novartis, Pfizer, Sanofi, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen, Bristol‑Myers Squibb, Johnson & Johnson, UCB S.A., Kiniksa Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Fresenius SE & Co KGaA, CSL Limited, Dr Reddy’s Laboratories, Tianjin Tianyao Pharmaceutical Co Ltd, Gilead Sciences Inc, Sobi AB

Global Giant-Cell Arteritis Market Trends and Insights

Major companies operating in the giant-cell arteritis are developing new products, such as biosimilar to expand treatment options and address the unmet medical needs of patients. A biosimilar is a biologic drug that is highly similar to an already approved biological product, with no clinically meaningful differences in terms of safety, purity, and potency. For instance, in April 2024, Fresenius SE & Co. KGaA, a Germany-based healthcare company, launched Tocilizumab-aazg in the US for treating chronic autoimmune diseases. This biosimilar is approved for conditions such as rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (JIA), polyarticular juvenile idiopathic arthritis (PJIA), and giant cell arteritis. Its approval was based on data from a randomized, double-blind, single-dose, parallel phase 1 trial comparing its pharmacokinetics, safety, and immunogenicity to both US and EU reference tocilizumab in three patient groups.

What Are Latest Mergers And Acquisitions In The Giant-Cell Arteritis Market?

In April 2023, Marksans Pharma, an India-based pharmaceutical company, acquired Teva’s manufacturing facility in Goa, India, for an undisclosed amount. As a result of the acquisition, Marksans gains a 47,597-square-meter facility. This will enable the company to double its existing capacity in India from the current level of 8 billion units per year, allowing for the production of tablets, hard and soft gel capsules, ointments, liquids, and creams. Teva Pharmaceutical is an Israel-based manufacturer of prednisone tablets for giant-cell arteritis treatment.

Regional Outlook

North America was the largest region in the giant-cell arteritis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Giant-Cell Arteritis Market?

The giant-cell arteritis market consists of revenues earned by entities by services such as monitoring and follow-up, supportive care, diagnostic testing, treatment administration. The market value includes the value of related goods sold by the service provider or included within the service offering. The giant-cell arteritis market also includes sales of biologics, diagnostic tools, biopsy kits and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Giant-Cell Arteritis Market Report 2026?

The giant-cell arteritis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the giant-cell arteritis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.